Terns Pharmaceuticals, Inc.: 10-Q filed 2023-11-14
What Terns Pharmaceuticals, Inc. reported in its quarterly report filed 2023-11-14 (fiscal Q3 2023): 37 published measures, 106 facts as tagged in accession 0000950170-23-063380.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-11-14
- Fiscal period
- fiscal Q3 2023
- Accession
- 0000950170-23-063380 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Terns Pharmaceuticals, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 271,687,000 | USD | |
| At 2022-12-31 | 287,026,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 13,262,000 | USD | |
| At 2022-12-31 | 10,083,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 258,425,000 | USD | |
| At 2023-06-30 | 274,150,000 | USD | |
| At 2023-03-31 | 287,683,000 | USD | |
| At 2022-12-31 | 276,943,000 | USD | |
| At 2022-09-30 | 183,694,000 | USD | |
| At 2022-06-30 | 137,216,000 | USD | |
| At 2022-03-31 | 148,716,000 | USD | |
| At 2021-12-31 | 160,303,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 37,893,000 | USD | |
| At 2022-12-31 | 143,235,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -29,767,000 | USD | 92 |
| 2023-04-01 to 2023-06-30 | -17,896,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -21,528,000 | USD | 90 |
| 2022-07-01 to 2022-09-30 | -16,820,000 | USD | 92 |
| 2022-04-01 to 2022-06-30 | -13,930,000 | USD | 91 |
| 2022-01-01 to 2022-03-31 | -13,773,000 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -48,074,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -37,898,000 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 8,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 241,000 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 28,089,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 61,125,000 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -85,219,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -7,726,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -311,609,000 | USD | |
| At 2022-12-31 | -242,418,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 71,530,180 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 70,897,320 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 38,511,655 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 29,743,579 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 71,530,180 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 70,897,320 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 38,511,655 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 29,743,579 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -0.42 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -0.98 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -0.44 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -1.5 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -0.42 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -0.98 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -0.44 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -1.5 | USD/shares | 273 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 58,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 190,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 13,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 40,000 | USD | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 526,000 | USD | |
| At 2022-12-31 | 757,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 22,254,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 8,081,000 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -33,184,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -78,500,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -17,292,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -45,201,000 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 270,455,000 | USD | |
| At 2022-12-31 | 285,185,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 12,087,000 | USD | |
| At 2022-12-31 | 8,468,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 3,325,000 | USD | |
| At 2022-12-31 | 1,645,000 | USD |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 61,785,216 | shares | |
| At 2022-12-31 | 53,723,171 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 570,864,000 | USD | |
| At 2022-12-31 | 520,178,000 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -836,000 | USD | |
| At 2022-12-31 | -822,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 671,000 | USD | |
| At 2022-12-31 | 1,047,000 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 770,000 | USD |
Long-term debt
Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 63,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 35,000 | USD | |
| At 2022-12-31 | 37,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 3,855,000 | USD | |
| At 2022-12-31 | 2,071,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -29,709,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -69,001,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -16,807,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -44,483,000 | USD | 273 |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -29,767,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -69,191,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -16,820,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -44,523,000 | USD | 273 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -29,828,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -69,205,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -16,927,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -45,533,000 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 18,353,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 32,462,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 5,131,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 16,242,000 | USD | 273 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 220,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 391,000 | USD | 273 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -5,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -69,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -14,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -64,000 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 3,475,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 9,499,000 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 485,000 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 718,000 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 1,959,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -251,000 | USD | 273 |
Inspect the source
- Entity
- Terns Pharmaceuticals, Inc. / CIK 0001831363
- Captured
- 2026-09-21T17:29:31.665Z
- SEC response SHA-256
4d742b360e76b44571af4457f65232e6efdd332ec4a2d6c091846b77989bf0e6
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001831363.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))